QuidelOrtho downgraded by Citigroup with a new price target
$QDEL
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Citigroup downgraded QuidelOrtho from Buy to Neutral and set a new price target of $72.00 from $95.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/8/2025 | $44.00 | Hold → Buy | Jefferies |
| 12/11/2024 | $44.00 → $50.00 | Neutral → Buy | Citigroup |
| 12/10/2024 | $43.00 | Hold | Jefferies |
| 9/19/2024 | $42.00 → $50.00 | Neutral | UBS |
| 9/5/2024 | $40.00 → $57.00 | Hold → Buy | Craig Hallum |
| 3/4/2024 | $70.00 → $42.00 | Neutral → Sell | UBS |
| 2/14/2024 | $66.00 → $37.00 | Neutral → Underweight | JP Morgan |
| 12/11/2023 | $95.00 → $72.00 | Buy → Neutral | Citigroup |